Following a routine review examining the safety and efficacy of the Pfizer-BioNTech by the external Independent Data Monitoring Committee (DMC), data has demonstrated that whilst there were no safety concerns,  immunogenicity of a two dose primary course consisting of 3µg doses in the 6 to 24 month-old cohort was met with non-inferiority, but not in the 2 – 5 year old group.

The company has also announced that it will resume studies evaluating a third  3µg dose of COVID-19 vaccine in children 6 months to under 5 years of age in order to select the right dose to maximise the risk-benefit profile in this age group. 

For further information on this study and its findings, follow the link below:  

Pfizer and BioNTech provide update on ongoing studies of COVID-19 vaccine